TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects
A legfontosabb adatok
- Ki végzi
- University Medical Center Groningen
- Hol
- Hollandia3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 939 fő vett részt
- Kezdés
- 2014. júl.
- Befejezés
- 2026. ápr.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Vena punction
- A regiszteradat frissítve
- 2025. szeptember 15.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki nem vehet részt
- Mental disorder (no informed consent available)
- Presence of active malignant disease
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
Egyéb feltételek
- All participating patients have to meet the following criteria:
- Alive
- TC diagnosis between 01-01-1976 to 31-12-2007
- TC treatment center: UMCG, NKI/AVL, Erasmus MC, UMCN, LUMC
- Younger than 50 years of age at TC diagnosis
- Written informed consent; Cases have to fulfill, beside the aforementioned criteria, the following criteria:
- Diagnosed with either myocardial infarction (MI), proven coronary artery disease (CAD) (CTCAE-4 grade 2 or higher) or congestive heart failure (CHF) (CTCAE-4 grade 2 or higher)
- No medical history of CVD before diagnosis of TC; In order to be eligible to participate in the cardiometabolic risk inventory study (and to be invited to a study assessment), a subject must meet, next to the criteria mentioned in "1)", the following inclusion criteria:
- Younger than 40 years of age at TC diagnosis
- Younger than 75 years of age at moment of inclusion
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late 1970s. Given the good prognosis of TC nowadays, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Current literature suggests that TC treatment, and specifically exposure to platinum agents, is associated with increased risk of cardiovascular morbidity and mortality. The precise role of treatment components like platinum in the pathogenesis of cardiometabolic changes and cardiovascular disease (CVD) warrants further investigation, since it is not known if CVD develops through direct platinum-induced damage of the vascular wall or by mediation through development of cardiometabolic riskfactors. The aim of this study is to identify risk factors for development for CVD after treatment for TC. A more profound insight into pathophysiologic mechanisms and identification of risk factors for CVDs is needed to facilitate development of preventive strategies and to optimize survivorship care.
A vizsgálat 2 csoportja
- Cases
Patients who developed cardiovascular disease after testicular cancer treatment
Kezelés: Vena punction
- Subcohort members
A random selection out of the total cohort of testicular cancer patients per participating hospital
Kezelés: Vena punction
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors
- Publikációk
- Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023
- A regiszteradat frissítve
- 2025. szeptember 15.